News - Aida Pharmaceuticals
Aida Pharmaceuticals has announced that it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer.
Aida Pharmaceuticals has announced that its recently-acquired research institute in the Jiangsu province, the Jiangsu Institute of Microbiology is developing a new wide-spectrum antibiotic, Wetimicin, in the People's Republic of China.
China-based Aida Pharmaceuticals said that its anticancer drug has performed well in Phase II field testing with efficacy in treating non-small cell lung cancer, non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer.
Aida Pharmaceuticals, one of mainland China's leading pharmaceutical companies, has completed its acquisition of the majority control of gene drug pioneer Shanghai Qiaer Bio-Technology Co.